After his Daily Show debacle in weeks past we don’t know if being recommended by Mad Money’s Jim Cramer is a good thing or a bad thing, but Carlsbadistan’s Isis Pharmaceutical was one of that man’s picks in what he calls the “Lightening Round” of his show, according to a story on Inveterms.com.
ISIS represents an attractive buyout opportunity for several reasons. First, the company saw its revenues climb 38% to $29.7 million with a switch from royalty revenue to R&D collaboration revenues. Second, the company is expected to end 2009 with more than $550 million in cash. Third, the company has a very positive outlook for 2009 with several key milestones on the horizon for its drugs.
Buy at your own risk.
[Link: Investerms.com]
RSS Feed-Posts